Construction of ASIC3shRNA interference lentiviral plasmid
and its efficiency validation
QU Xue-fei1,2, HUA Jia2, WU Jin2, GONG Ai-hua1, JIANG Peng2
(1. School of Medicine, Jiangsu University, Zhenjiang Jiangsu 212013; 2. Department of Anesthesiology, Affiliated Hospital of Jiangsu University, Zhenjiang Jiangsu 212001, China)
Abstract:Objective: To construct lentiviral interference plasmid of acidsensing ion channel 3(ASIC3) and validate the efficiency. Methods: ASIC3 gene sequence was obtained from Genbank to synthesize the corresponding interference sequence. Then it was inserted into the circular Plko.1Puro vector by T4 DNA ligase. The recombinant plasmid was transfected into 293T cells for lentivirus, and the obtained lentivirus was determined for titer by quantitative realtime PCR(qRTPCR). PC12, BV2 and N2a cells were infected with the packaging lentivirus, and divided into ASIC3shRNA group and EGFPshRNA group(negative control). After lentivirus infection, qRTPCR and western blotting were used to detect the expression of ASIC3 mRNA and protein, respectively. Results: The synthetic ASIC3 interference sequence was successfully inserted into Plko.1Puro vector. qRTPCR and DNA testing confirmed the successful construction of the ASIC3shRNA plasmid, the virus titer was approximately 1×109 IU/mL. The expression of ASIC3 mRNA and protein in PC12, BV2 and N2a cells were significantly downregulated in ASIC3shRNA group compared with EGFPshRNA group(P<0.05). Conclusion: The ASIC3shRNA interference lentivirus plasmid was successfully constructed.
基金资助:镇江社会发展科技支撑项目(SH2014078)
通讯作者:
蒋鹏(通讯作者),主任医师,E-mail: doctorjp@163.com
作者简介: 曲雪菲(1992—),女,硕士研究生
引用本文:
曲雪菲, 华佳, 吴进, 龚爱华, 蒋鹏. ASIC3-shRNA干扰慢病毒质粒的构建及其效率的鉴定[J]. 江苏大学学报:医学版, 2019, 29(01): 58-61.
QU Xue-fei1,2, HUA Jia2, WU Jin2, GONG Ai-hua1, JIANG Peng2. Construction of ASIC3shRNA interference lentiviral plasmid
and its efficiency validation. Journal of Jiangsu University(Medicine Edition), 2019, 29(01): 58-61.
[1]Zhu H, Ding J, Wu J, et al. Resveratrol attenuates bone cancer pain through regulating the expression levels of ASIC3 and activating cell autophagy\[J\]. Acta Biochim Biophys Sin (Shanghai), 2017,49(11):1008-1014.[2]Yen YT, Tu PH, Chen CJ, et al. Role of acidsensing ion channel 3 in subacutephase inflammation\[J\]. Mol Pain, 2009, 5:1.[3]Ni L, Fang P, Hu ZL, et al. Identification and function of acidsensing ion channels in RAW 264.7 macrophage cells\[J\]. Curr Med Sci, 2018, 38(3):436-442.[4]Deval E, Gasull X, Noёl J, et al. Acidsensing ion channels(ASICs): pharmacology and implication inpain\[J\]. Pharmacol Ther, 2010,128(3):549-558.[5]Deval E, Noёl J, Lay N, et al. ASIC3, a sensor of acidic and primary inflammatory pain\[J\]. EMBO J, 2008, 27(22):3047-3055.[6]Hiasa M, Okui T, Allette YM, et al. Bone pain induced by multiple myeloma is reduced by targeting VATPase and ASIC3\[J\]. Cancer Res, 2017, 77(6):1283-1295.[7]Izurieta Munoz H, Gonzales EB, Sumien N. Effects of creatine supplementation on nociception in young male and female mice\[J\]. Pharmacol Rep, 2017, 70(2): 316-321.[8]Ren P, Wang WB, Pan HH, et al. Upregulation of ASIC3 expression by βestradiol\[J\]. Neurosci Lett, 2018, 684:200-204.[9]HerreraCarrillo E, Liu YP, Berkhout B. Improving miRNA delivery by optimizing miRNA expression cassettes in diverse virus vectors\[J\]. Hum Gene Ther Methods, 2017, 28(4):177-190.[10]Liu YP, Berkhout B. miRNA cassettes in viral vectors: problems and solutions\[J\].Biochim Biophys Acta, 2011, 1809(11/12): 732-745.[11]孟凡荣,陈琛,万海粟,等.慢病毒载体及其研究进展\[J\].中国肺癌杂志, 2014,17(12): 870-876.[12]Sioud M. RNA interference: mechanisms, technical challenges, and therapeutic opportunities\[J\]. Methods Mol Biol, 2015, 1218: 1-15.[13]Wu P, Wilmarth MA, Zhang F, et al. miRNA and shRNA expression vectors based on mRNA and miRNA processing\[J\]. Methods Mol Biol, 2013, 936:195-207.[14]Lambeth LS, Smith CA. Short hairpin RNAmediated gene silencing\[J\]. Methods Mol Biol, 2013, 942: 205-232.[15]ter Brake O, Westerink JT, Berkhout B. Lentiviral vector engineering for antiHIV RNAi gene therapy\[J\]. Methods Mol Biol, 2010, 614:201-213.